Horizon Therapeutics (NASDAQ:HZNP) Stock Rating Upgraded by BMO Capital Markets
BMO Capital Markets upgraded shares of Horizon Therapeutics (NASDAQ:HZNP) from a market perform rating to an outperform rating in a report published on Wednesday, BenzingaRatingsTable reports. They currently have $36.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $29.00.
Several other equities research analysts also recently issued reports on the stock. BidaskClub downgraded shares of Horizon Therapeutics from a hold rating to a sell rating in a research note on Friday, July 26th. Citigroup raised shares of Horizon Therapeutics from a neutral rating to a buy rating and boosted their target price for the stock from $21.00 to $32.00 in a research report on Wednesday, May 1st. Cowen set a $35.00 target price on shares of Horizon Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 7th. TheStreet downgraded shares of Horizon Therapeutics from a b- rating to a c+ rating in a research report on Monday, June 10th. Finally, Mizuho set a $27.00 target price on shares of Horizon Therapeutics and gave the stock a hold rating in a research report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Horizon Therapeutics currently has a consensus rating of Buy and a consensus target price of $32.73.
Horizon Therapeutics stock opened at $27.00 on Wednesday. Horizon Therapeutics has a 12-month low of $16.56 and a 12-month high of $29.44. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 14.75, a price-to-earnings-growth ratio of 1.57 and a beta of 0.88. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 1.68. The firm’s fifty day moving average price is $24.68 and its 200 day moving average price is $25.04.
In other news, insider Jeff Kent sold 3,620 shares of Horizon Therapeutics stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total value of $89,196.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Geoffrey M. Curtis sold 20,609 shares of Horizon Therapeutics stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $26.58, for a total transaction of $547,787.22. Following the completion of the transaction, the executive vice president now directly owns 28,382 shares of the company’s stock, valued at $754,393.56. The disclosure for this sale can be found here. Insiders sold a total of 48,480 shares of company stock valued at $1,230,599 in the last three months. Insiders own 4.10% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of HZNP. FMR LLC boosted its holdings in shares of Horizon Therapeutics by 165.1% in the 1st quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock valued at $137,575,000 after buying an additional 3,242,071 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Horizon Therapeutics by 1,910.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock valued at $40,249,000 after buying an additional 1,589,614 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Horizon Therapeutics in the 1st quarter valued at about $27,663,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Horizon Therapeutics by 1,774.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock valued at $26,508,000 after buying an additional 1,042,969 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Horizon Therapeutics by 11.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock valued at $210,628,000 after buying an additional 896,500 shares during the period. 87.83% of the stock is owned by institutional investors and hedge funds.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Understanding Analyst Ratings
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.